Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2023-03-30 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
2022年度独立董事述职报告可钰
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2022 of Henan Xintiandi Pharmaceutical Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various board matters, committee participation, and efforts to protect investor rights. The content focuses on the director's duties, meeting participation, and governance oversight rather than financial results or audit opinions. It is a report on the independent director's activities and responsibilities rather than a full annual report, audit report, or regulatory filing. This type of document aligns with Board/Management Information (MANG) as it relates to management and board activities and disclosures about governance roles and responsibilities. The document length is 3046 characters, which is relatively short but contains substantive content about board and management activities, not just an announcement or certification. Therefore, the best classification is MANG with high confidence.
2023-03-30 Chinese
独立董事关于对第五届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on various board meeting agenda items, including internal control reports, fundraising usage reports, profit distribution plans, and remuneration proposals. It references compliance with laws and regulations and expresses agreement with proposals to be submitted to the shareholders' meeting. The document is not a full annual report, audit report, or financial statement but rather a formal opinion related to board meeting matters. It is not a simple announcement or certification but a detailed management/board-related report. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board or senior management matters and opinions related to board meetings.
2023-03-30 Chinese
2022年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from the board of directors of 河南新天地药业股份有限公司 regarding the 2022 annual status of raised funds, including their storage, management, and actual usage. It references regulatory approvals, specific financial figures related to fundraising, usage, and balances, and includes auditor and sponsor institution opinions on the compliance and accuracy of the report. The document is comprehensive, contains substantive financial data, and focuses on the use of capital raised through stock issuance. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report publication, nor a general regulatory filing, but a detailed report on fundraising usage and management. Therefore, the appropriate classification is CAP with high confidence.
2023-03-30 Chinese
关于公司及其控股子公司使用闲置自有资金购买结构性存款或理财产品的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Henan Xintiandi Pharmaceutical Co., Ltd. regarding the company's and its subsidiaries' use of idle funds to purchase structured deposits or wealth management products. It includes details about the investment purpose, amount, duration, and approval process, including board meeting resolutions and independent director opinions. The document is relatively short (1273 characters) and serves as a formal announcement of a financing-related decision rather than a detailed financial report or earnings release. It does not contain financial statements or detailed financial data but rather informs shareholders and the public about a capital usage plan. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-03-30 Chinese
关于使用银行承兑汇票方式支付募投项目所需资金并以募集资金等额置换的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Henan Xintiandi Pharmaceutical Co., Ltd. regarding the use of bank acceptance bills and other notes to pay for funds required for a fundraising investment project and the replacement of an equivalent amount of raised funds. It includes details about board and supervisory committee meetings, independent director opinions, and sponsor institution opinions. The document references regulatory approvals and fundraising details but does not contain actual financial statements or detailed financial performance data. The document length is 3282 characters, which is relatively short and primarily serves as an official announcement of a financing-related operational decision. This fits the description of a Capital/Financing Update (CAP) rather than a full financial report or other categories.
2023-03-30 Chinese
监事会关于公司2022年度内部控制自我评价报告的核查意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board's opinion on the company's 2022 internal control self-evaluation report. It references regulatory requirements and internal control standards but does not contain the full internal control report itself. The document is relatively short (941 characters) and appears to be a formal opinion or verification statement rather than the full report. This fits the category of an Audit Report / Information (AR), as it relates to internal control evaluation and supervisory board review, which is typical for audit-related disclosures but is not a full annual report or financial statement. Therefore, the best classification is AR with high confidence. FY 2022
2023-03-30 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.